GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)

Next Previous
Trial Profile

GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Antithrombotics
  • Indications Stroke; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GLORIA-AF
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 27 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Sep 2017 Results (n=2932) of part 2 assessing the predictors of dabigatran etexilate persistence over 2 years of follow-up in patients with newly diagnosed atrial fibrillation, published in the Journal of the American College of Cardiology.
    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top